Latest news and press releases about Achieve Life Sciences, Inc. (ACHV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom.
Price
| Price | $7.42 |
| Market Cap | $762M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -48.65 |
| EV / EBITDA | -7.43 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -892.07% |
| Return on Invested Capital | -21425.74% |
| Return on Assets | -59.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLO · ARCT · AVIR · CAPR · HUMA · IMRX · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ACHV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks